Abstract: An aligned and multichannel peripheral nerve conduit, including Polyvinyl alcohol (PVA) and graphene oxide (GO) with aligned and multichannel design for peripheral nerve repair. 3D printing technology with assembly is utilized to make a specific mold to get a multichannel design to mimic natural peripheral nerves. Directional freeze casting is used to form an aligned PVA/GO hydrogel structure to guide cell growth.

Abstract: The present invention provides a JAK inhibitor having high oral bioavailability, characterized in that the JAK inhibitor includes: a Formula I compound, or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, or pharmaceutically acceptable salt thereof as an active ingredient. The JAK inhibitor with high oral bioavailability provided by the present invention can overcome the problem that existing JAK inhibitors have low oral bioavailability, and involves further modifying a chemical compound so as to change the physicochemical characteristics of one or several small molecule compounds, thus increasing the in-vivo cell absorption performance of said compound(s), greatly improving the bioavailability of the medication and providing new possibilities for drug delivery and utilization for said compound medication.

Abstract: Provided is a small molecule compound, which is characterized in having the structure represented by the following molecular formula: (I), wherein X1 and X2 are selected from carbon or nitrogen; G1 is a carbocyclic ring or heterocyclic ring having aromaticity; any one or more hydrogen atoms on the ring of G1 are substituted by R1; and R1 is selected from nitrogen-containing groups. The small molecule compound of the present invention can be used as a highly effective and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor; and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 or Tyk2/JAK1, Tyk2/Jak2 dual inhibitor.

Abstract: A triazolo pyrazine compound, wherein the triazolo pyrazine compound is a compound as represented by formula (I) as follows, or a stereoisomer, a geometrical isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or a prodrug thereof, wherein W is selected from a substituted or unsubstituted aryl or heteroaryl, X is C or N, and R is H or any substituent group. When the triazolo pyrazine compound provided by the invention is used as a Tyk2 specific inhibitor, a more targeted drug can be provided for autoimmune inflammatory diseases driven by an IL-23/Th17 axis, and the compound can be used for treating rheumatoid arthritis, psoriasis, ankylosing spondylitis, sicca syndrome, lupus erythematosus, inflammatory bowel disease, Behcet's disease, severe COVID-19 pneumonia and other diseases more safely and effectively.

Abstract: The present invention provides a small molecule compound. The small molecule compound is a compound represented by the following formula (I), or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, and pharmaceutically acceptable salt or prodrug thereof, wherein R1 to R5 are each independently selected from C or N; and R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl. The small molecule compound of the present invention can inhibit the JAK kinase, and is particularly used as a JAK1/Tyk2 dual inhibitor and a Tyk2 specific inhibitor.

Abstract: Provided in the present invention are a small molecule compound, which is the compound represented by formula (I), or a stereoisomer, a geometric isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or a prodrug thereof, where R1 to R4 are each independently selected from C or N, and wherein R is selected from a cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl. The small molecule compound of the present disclosure can inhibit a JAK kinase, and more particularly is used as a JAK1/Tyk2 dual inhibitor and a Tyk2 specific inhibitor.

Abstract: Provided in the present invention is a small molecule compound, which is characterized in that it is a compound or a stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite, and pharmaceutically acceptable salt or prodrug of the compound as represented by the following structural formula: formula (I). The small molecule compound of the present invention is applicable as a highly efficient and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor.

Abstract: A method and an apparatus for managing a conference call, a terminal and a network device are provided. The method includes transmitting a first request to a network during a current conference call, so that the network can control at least one end of the current conference call not to transmit service data, or the network cannot forward the service data of the at least one end to other ends of the conference call, or the network can forward the service data of the at least one end to designated ends of the conference call. Designated subscribers in a conference call can be muted and a partial conference can be made among designated subscribers of a conference call, and the designated subscribers can be stopped from being muted and the conference call among all ends can be restored, thereby satisfying diversified requirements of users.